Grants for Small businesses - Health

The Arizona Department of Health Services (ADHS) Bureau of Women’s and Children’s Health (BWCH) oversees Adolescent Health programming to improve the health and well-being of young people in the state. As of 2005, BWCH has been administering state lottery funds for the prevention of teen pregnancies and sexually transmitted infections (STIs). According to the Arizona Vital Statistics, from 2011 to 2021, the teen birth rate for Arizona teenagers ages fifteen through nineteen (15-19) has declined from thirty-six point nine (36.9) to fifteen point three (15.3) per 1,000 females. The repeat birth rates of youth of the same age, who had already had a child decreased from 142.7 in 2011 to 135.8 per 1,000 in 2021. Despite the declines, birth rates for Arizona teens ages fifteen through nineteen (15-19)   exceeds   the   national   rate   of   thirteen   point   nine   (13.9)   in   2021 (https://blogs.cdc.gov/nchs/2023/01/20/7245/). Arizona's racial and ethnic groups exhibit significant disparities in teen pregnancy rates, with Hispanic, American Indian, and African American females aged nineteen (19) or younger experiencing the highest rates. In 2021, American Indian youth had a notably elevated pregnancy rate of sixteen point three (16.3) per 1,000 females, surpassing the state average of ten point six (10.6) per 1,000. Similarly, rates for Hispanic or Latino youth were fourteen point four (14.4) per 1,000, and for Black or African American youth, they were twelve point six (12.6) per 1,000, both above the state average, while rates for White Non-Hispanics six (6) per 1,000 and Asian or Pacific Islanders three point four (3.4) per 1,000 were considerably lower. Teen pregnancy is intricately linked with complex factors such as school failure, behavioral issues, and family challenges, which often hinder youths’ ability to avoid pregnancy. Positive Youth Development (PYD) programs present a promising approach by emphasizing the enhancement of protective factors over merely addressing risk behaviors. These programs have shown efficacy in reducing sexual risk behaviors, Human immunodeficiency virus (HIV), other sexually transmitted diseases (STDs), and unintended pregnancies. By fostering ongoing development and maturation, PYD programs empower youth to recognize and manage risk-taking behaviors, making them a viable strategy for teen pregnancy prevention (Gavin et al., 2010). According to the 2021 Arizona Surveillance STD case data, forty-nine percent (49%) of STD cases (chlamydia, gonorrhea, and syphilis) in Arizona were among adolescents under the age of twenty-five (25). Since 2019, the rate of chlamydia among teenagers fifteen through nineteen (15-19) years old has been slowly decreasing but still remains high at 2,031 per 100,000 in 2019 to 1,729 per 100,000 in 2021. For gonorrhea, the rate among these teenagers increased from 384 per 100,000 in 2019 to 467 per 100,000 in 2021. As for syphilis, in 2019, twenty-two (22) per 100,000 fifteen through nineteen (15-19) year-old teenagers were reported to have syphilis, increasing to twenty-six (26) per 100,000 in 2021. Regarding STDs/STIs, major disparities between Arizona’s racial and ethnic groups also persist. The Arizona 2021 Annual STD Report indicates that Black (994 per 100,000) and American Indian/Alaska Native (787 per 100,000) populations have consistently higher rates of chlamydia, the Black population (763 per 100,000) continues to have the highest rate of gonorrhea, and the American Indian/Alaska Native (172 per 100,000) and Black (123 per 100,000) populations have the highest rates of syphilis, surpassing their Hispanic, White, and Asian/Pacific Islander counterparts. Financial Notes: Approximately $700,000.00 will be available each Grant year for a five (5) year grant period to provide services to youth for the prevention of teen pregnancies and STIs. Annual funding for services will be provided during the state fiscal year, from July through June; Therefore, the first and last years of funding will be partial funding: first year funded upon award through June 30, 2025; fifth year from July 1, 2029 through September 30, 2029. Budgets will be reviewed annually and may be decreased based on: 1. Changes in state lottery funding allocations. 2. Failure to meet the number of youths proposed to be served; or meet the required program completion by youth for Teen Pregnancy Prevention Programming. 3. Failure to comply with Grant requirements. 4. Negative audit findings. 5. Failure to spend budget funds efficiently.

This funding opportunity supports researchers in developing and testing innovative medical devices aimed at treating or diagnosing conditions affecting the nervous and neuromuscular systems.

This funding opportunity supports multidisciplinary teams in developing innovative bioengineering technologies to address specific biomedical challenges, with eligibility for a wide range of organizations including universities, nonprofits, and small businesses.

This funding opportunity provides financial support to various organizations to develop and implement evidence-based self-management programs that improve health knowledge and reduce complications for individuals affected by blood disorders like hemophilia and thalassemia.

The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications encouraging foundational research projects that seek to refine and test valid methods for characterizing preteen suicide risk and protective factors across multiple domains, and for operationalizing suicide thoughts and behavior (STBs) and nonsuicidal self-injury (NSSI) among preteen youth (ages 8-12). An emphasis is placed on the inclusion of sub-populations of youth that experience health disparities and may have been underrepresented in prior youth suicide research. Studies may focus on developing new or adapting developmentally and culturally appropriate methods for assessing and characterizing risk and protective factors, examining the acceptability and utility of existing assessment methods, evaluating the relevance of risk and protective factors for diverse preteen youth and their families, modeling risk-factor trajectories, and refining sampling strategies. The research projects funded through this announcement will participate in a research consortium with other R01 recipients. In addition, each research site will work with the Data Coordinating Center (DCC) site (supported by a companion announcement) to share and analyze data, recommend candidate measures that will be included as common data elements in future research and practice contexts,and identify optimal approaches for sampling individuals from underrepresented backgrounds. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects, and to consult with NIH in order to submit responsive applications. The NOFO is expected to be published in Summer 2023, with an expected application due date in Fall 2023. This NOFO will utilize the R01 activity code. Details of the planned NOFO are provided below.

This funding opportunity supports research projects that develop and implement effective strategies to reduce overdose deaths and improve addiction treatment across various settings, targeting diverse populations and addressing health disparities.

This grant provides funding for researchers and organizations to develop innovative medical countermeasures for treating acute chemical exposures resulting from terrorist attacks or accidental releases, enhancing national preparedness for chemical emergencies.

This funding opportunity provides financial support for researchers and organizations developing innovative long-acting treatments for HIV and related co-infections, aiming to improve patient adherence and health outcomes.

This funding opportunity supports innovative research aimed at developing new strategies for curing HIV at the start of antiretroviral therapy, targeting researchers and institutions focused on reducing the HIV reservoir and improving immune responses.

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The Women’s Business Development Council (WBDC) is offering the Torrington Grant Program, a grant designed to foster the growth of businesses located in Torrington, Connecticut. This initiative aligns with the WBDC's mission to support and empower businesses, particularly by providing crucial financial assistance that can contribute to economic development within the targeted city. The program specifically excludes the use of funds for operating expenses, real estate improvements, reimbursement for past purchases, or debt repayment, emphasizing a focus on growth-oriented investments rather than day-to-day operational costs. The primary beneficiaries of this grant are for-profit businesses situated in Torrington, Connecticut, that meet specific criteria. These businesses must have been in operation for at least two years with a record of sales, demonstrate annual sales/revenue between $25,000 and $2,000,000 in the last twelve months, be registered in Connecticut, and hold a zoning permit from the City of Torrington. Additionally, they must be in good standing with the CT Department of Revenue Services, possess an established business checking account, and utilize a formal digital bookkeeping/financial system. The owner must also be at least 18 years old. The impact goal is to stimulate economic vitality and stability within Torrington by supporting established local businesses. The program prioritizes businesses that are poised for growth and are operating within a structured financial framework. There is a clear focus on financial transparency and stability, as evidenced by the requirement for digital bookkeeping systems and good standing with the Department of Revenue Services. Certain types of businesses are explicitly ineligible, including childcare businesses (though WBDC offers other programs for them), businesses that have previously received a WBDC grant, current WBDC vendors or contractors, and a range of businesses such as medical marijuana, liquor stores, adult businesses, vape/tobacco shops, gambling-related businesses, gun stores, cash advance/pawn shops, and collection agencies. This selectivity ensures that the grants are directed towards businesses that align with the WBDC's strategic vision for community development and ethical business practices. Grants will range from $2,500 to $10,000. The expected outcomes include a measurable increase in the capacity and reach of the recipient businesses, contributing to job creation and sustained economic activity within Torrington. By providing financial resources to qualifying businesses, the WBDC aims to strengthen the local business ecosystem and encourage long-term prosperity. This grant program is a direct manifestation of the WBDC's strategic priority to support local economies through targeted financial aid, operating under the theory of change that direct investment in compliant, established businesses will lead to enhanced economic stability and growth.

This funding opportunity provides financial support to organizations working to improve laboratory diagnostics and monitoring for HIV/AIDS care and treatment in Jamaica and Trinidad and Tobago, enhancing public health outcomes in the Caribbean.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

This funding opportunity provides financial support to small businesses in the U.S. for conducting early-phase clinical trials of innovative treatments for neurological disorders.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.

This funding opportunity provides financial support for researchers to analyze and integrate existing data to better understand cancer risk, prevention, and treatment outcomes, particularly focusing on innovative methodologies and addressing health disparities.

This ISO seeks solution summaries and proposal submissions for projects that fall within the general scope of the ARPA-H Health Science Futures (HSF) mission office. HSF expands what is technically possible by developing approaches that will remove the scientific and technological limitations that stymie progress towards the healthcare of the future. HSF supports cutting-edge, often disease-agnostic research programs that have the potential for translational real-world change.Considering the current healthcare challenges that we face today, the goal of achieving better health outcomes is a moving target that requires daring and adaptable solutions. HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support:Breakthrough Technologies: Paradigm shifting technologies that will change how we approach the diagnosis, treatment, and impact of diseases and conditions. Novel approaches to improve maternal and fetal medicine, decrease maternal morbidity and mortality during birth, and the post-partum period. Efforts should include new technology to monitor, detect, and/or treat maternal and/or fetal complications with less invasive and traumatic methods. Foundational advances in genetic, epigenetic, cellular, tissue, and organ replacement therapies that enable personalized medical interventions at scale in a manner that is accessible, cost-effective, and designed to impact the communities of greatest need. Interventions that target and reverse disease pathogenesis and/or enhance plasticity to address diseases of the nervous, neuromuscular, skeletal, lymphatic, cardiovascular, and other organ systems. Novel approaches to diagnose and treat diseases of the lymphatic system, particularly rare diseases, with a focus on the effects of genetic expression in the lymphatic system and/or models demonstrating the relationship between lymphatic dysfunction and health and disease.Transformative Tools: Novel, agile solutions that will move from bench to bedside quickly, facilitating revolutionary advances in medical care. Development of tools that counter idiosyncratic, off-target, or chronic effects of medicines that are commonly used or that are being used experimentally to treat or prevent disease. Development of bionics to restore sight, hearing, taste, or smell. Site-selective neuromodulation to regulate specific physiological functions and treat chronic health conditions such as inflammation, pain, and metabolic or endocrine disorders. Synthetic biology approaches to diagnosing, treating, and/or curing a multitude of diseases. Novel physics and/or chemistry-based approaches to improve imaging that reduces cost, increases availability, expands capability, improves resolution, reduces exposure to radiation, and accommodates pediatric patient populations. Integrated sensing and delivery devices for treating and diagnosing chronic health conditions, including mental health conditions or substance use disorders. Miniaturization of complex hardware to enable broader access to pediatric and other patient populations, as well as portability, such as diagnostic, treatment, imaging, or other devices.Platform Systems: Adaptable, multi-application systems and technologies that are reconfigurable for a wide variety of clinical needs Novel molecular platform approaches, including the modulation of host systems, delivery to targets with spatial and temporal precision, and mitigation of off-target effects to accelerate interventions that dramatically improve health outcomes. New approaches to accelerate and routinize mammalian and microbial cellular engineering to enable next generation therapeutic applications, develop multiscale interventions, and automate hypothesis generation and discovery to expand those applications to disease states in which cellular therapies have not traditionally been employed. Innovative approaches at the intersection of artificial intelligence, high performance computing (including quantum computing) and biological systems, including enabling de novo design of biomolecules with entirely new phenotypes.Other high-quality submissions that propose revolutionary technologies that meet the goals of HSF will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy changes, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

This funding opportunity supports multidisciplinary research aimed at improving the understanding and treatment of asthma and allergic diseases, inviting applications from various institutions and organizations involved in clinical and translational research.

This funding opportunity provides financial support for researchers to plan and prepare for clinical trials focused on infectious, immunologic, and allergic diseases, ensuring they have the necessary resources and documentation for future trial implementation.

This funding opportunity supports research initiatives aimed at preventing community violence among youth and young adults, particularly those addressing racial and ethnic disparities, with grants available to governments, educational institutions, and non-profits.